EUR 169.2
(5.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 3.34 Billion EUR | -8.54% |
2022 | 3.65 Billion EUR | -12.27% |
2021 | 4.16 Billion EUR | 9.35% |
2020 | 3.8 Billion EUR | 9.27% |
2019 | 3.48 Billion EUR | 1.51% |
2018 | 3.43 Billion EUR | 4.89% |
2017 | 3.27 Billion EUR | 11.17% |
2016 | 2.94 Billion EUR | 8.31% |
2015 | 2.71 Billion EUR | 18.68% |
2014 | 2.29 Billion EUR | 5.67% |
2013 | 2.16 Billion EUR | -8.83% |
2012 | 2.37 Billion EUR | 6.49% |
2011 | 2.23 Billion EUR | 3.14% |
2010 | 2.16 Billion EUR | 3.54% |
2009 | 2.09 Billion EUR | -14.83% |
2008 | 2.45 Billion EUR | -4.81% |
2007 | 2.57 Billion EUR | 30.12% |
2006 | 1.98 Billion EUR | 10.66% |
2005 | 1.79 Billion EUR | -31.28% |
2004 | 2.6 Billion EUR | 8.7% |
2003 | 2.39 Billion EUR | -24.58% |
2002 | 3.17 Billion EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 1.94 Billion EUR | 0.0% |
2023 Q2 | 1.68 Billion EUR | 0.0% |
2023 FY | 3.34 Billion EUR | -8.54% |
2023 Q4 | 1.65 Billion EUR | 0.0% |
2022 FY | 3.65 Billion EUR | -12.27% |
2022 Q2 | 1.98 Billion EUR | 0.0% |
2022 Q4 | 1.66 Billion EUR | 0.0% |
2021 Q2 | 2 Billion EUR | 0.0% |
2021 FY | 4.16 Billion EUR | 9.35% |
2021 Q4 | 2.16 Billion EUR | 0.0% |
2020 FY | 3.8 Billion EUR | 9.27% |
2020 Q4 | 1.96 Billion EUR | 0.0% |
2020 Q2 | 1.84 Billion EUR | 0.0% |
2019 Q4 | 1.84 Billion EUR | 0.0% |
2019 FY | 3.48 Billion EUR | 1.51% |
2019 Q2 | 1.64 Billion EUR | 0.0% |
2018 Q2 | 1.69 Billion EUR | 0.0% |
2018 FY | 3.43 Billion EUR | 4.89% |
2017 Q4 | 1.66 Billion EUR | 0.0% |
2017 FY | 3.27 Billion EUR | 11.17% |
2017 Q2 | 1.61 Billion EUR | 0.0% |
2016 FY | 2.94 Billion EUR | 8.31% |
2016 Q2 | 1.42 Billion EUR | 0.0% |
2015 FY | 2.71 Billion EUR | 18.68% |
2015 Q4 | 1.35 Billion EUR | 0.0% |
2015 Q2 | 1.36 Billion EUR | 0.0% |
2014 Q4 | 1.18 Billion EUR | 0.0% |
2014 FY | 2.29 Billion EUR | 5.67% |
2014 Q2 | 1.1 Billion EUR | 0.0% |
2013 Q4 | 1.02 Billion EUR | 0.0% |
2013 Q2 | 1.13 Billion EUR | 0.0% |
2013 FY | 2.16 Billion EUR | -8.83% |
2012 Q3 | 594.5 Million EUR | 0.0% |
2012 FY | 2.37 Billion EUR | 6.49% |
2012 Q4 | 574.25 Million EUR | -3.41% |
2012 Q2 | 594.5 Million EUR | 0.0% |
2012 Q1 | 594.5 Million EUR | 0.0% |
2011 Q1 | 558.25 Million EUR | 0.0% |
2011 Q2 | 558.25 Million EUR | 0.0% |
2011 Q3 | 558.25 Million EUR | 0.0% |
2011 Q4 | 594.5 Million EUR | 6.49% |
2011 FY | 2.23 Billion EUR | 3.14% |
2010 Q4 | 558.25 Million EUR | 3.14% |
2010 Q2 | 541.25 Million EUR | 0.0% |
2010 Q3 | 541.25 Million EUR | 0.0% |
2010 Q1 | 541.25 Million EUR | 0.0% |
2010 FY | 2.16 Billion EUR | 3.54% |
2009 Q4 | 541.25 Million EUR | 3.54% |
2009 FY | 2.09 Billion EUR | -14.83% |
2009 Q2 | 522.75 Million EUR | 0.0% |
2009 Q3 | 522.75 Million EUR | 0.0% |
2009 Q1 | 522.75 Million EUR | 0.0% |
2008 Q3 | 613.75 Million EUR | 0.0% |
2008 FY | 2.45 Billion EUR | -4.81% |
2008 Q1 | 613.75 Million EUR | 0.0% |
2008 Q2 | 613.75 Million EUR | 0.0% |
2008 Q4 | 522.75 Million EUR | -14.83% |
2007 Q4 | 613.75 Million EUR | -4.81% |
2007 FY | 2.57 Billion EUR | 30.12% |
2007 Q3 | 644.75 Million EUR | 0.0% |
2007 Q2 | 644.75 Million EUR | 0.0% |
2007 Q1 | 644.75 Million EUR | 0.0% |
2006 Q3 | 495.5 Million EUR | 0.0% |
2006 Q4 | 644.75 Million EUR | 30.12% |
2006 Q2 | 495.5 Million EUR | 0.0% |
2006 FY | 1.98 Billion EUR | 10.66% |
2006 Q1 | 495.5 Million EUR | 0.0% |
2005 Q4 | 495.5 Million EUR | 10.66% |
2005 FY | 1.79 Billion EUR | -31.28% |
2005 Q2 | 447.75 Million EUR | 0.0% |
2005 Q3 | 447.75 Million EUR | 0.0% |
2005 Q1 | 447.75 Million EUR | 0.0% |
2004 Q2 | 651.58 Million EUR | 0.0% |
2004 FY | 2.6 Billion EUR | 8.7% |
2004 Q1 | 651.58 Million EUR | 0.0% |
2004 Q3 | 651.58 Million EUR | 0.0% |
2004 Q4 | 447.75 Million EUR | -31.28% |
2003 Q4 | 651.58 Million EUR | 8.7% |
2003 Q3 | 599.4 Million EUR | 0.0% |
2003 Q1 | 599.4 Million EUR | 0.0% |
2003 Q2 | 599.4 Million EUR | 0.0% |
2003 FY | 2.39 Billion EUR | -24.58% |
2002 Q3 | 794.77 Million EUR | 0.0% |
2002 Q2 | 794.77 Million EUR | 0.0% |
2002 Q1 | 794.77 Million EUR | 0.0% |
2002 FY | 3.17 Billion EUR | 0.0% |
2002 Q4 | 599.4 Million EUR | -24.58% |
2001 Q4 | 794.77 Million EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Nicox S.A. | -11.5 Million EUR | 29153.29% |
European Medical Solutions | 13.51 Million EUR | -24635.401% |
FERMENTALG | 535 Thousand EUR | -624572.897% |
argenx SE | 925.49 Million EUR | -261.103% |
BioSenic S.A. | 543 Thousand EUR | -615369.613% |
Celyad Oncology SA | 33 Thousand EUR | -10127172.727% |
Hyloris Pharmaceuticals SA | 1.99 Million EUR | -167502.808% |
Onward Medical N.V. | -14.81 Million EUR | 22653.651% |
Oxurion NV | 104 Thousand EUR | -3213361.538% |
PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -251936.199% |
Financière de Tubize SA | -2.02 Million EUR | 164764.205% |